Evommune, Inc.
NYSE:EVMNBiotechnology
Healthcare
$7.02 -0.82%
-$0.17 today
- Market cap
- $290.28M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
52W Low $13.89High $33.20
Volume 0.90M
Average 0.38M
Income Statement
Follow revenue through to earnings.
Revenue
$13.00M
FY 2025 · Annual
+85.7% YoYOperating Income
-$81.07M
FY 2025 · Annual
Net Income
-$68.87M
FY 2025 · Annual
Income Statement
USD
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| 30.08M | 30.08M | 31.52M | |
| 30.08M | 30.08M | 31.52M |
EVMN Earnings Waterfall · TTM
NYSE:EVMN · Revenue to Net Income
Key Ratios
EPS$-2.39
Gross Margin25.0%
Net Margin-31.2%
P/E Ratio-9.4
P/S Ratio15.9
Analysis
$10.0M of revenue converted into -$76.0M of net income for the selected period. Gross margin is 25.0% and net margin is -31.2%, showing how much revenue survives after costs and taxes. EPS is $-2.39, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 424B3 | 424B3 filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
How much revenue does EVMN generate?
Evommune, Inc. (EVMN) reported $13.00M of revenue in fiscal 2025.
Is EVMN profitable?
Evommune, Inc. (EVMN) reported -$68.87M of net income, with a net margin of -529.8%.
Continue the stock analysis
Jump to another research area for this company.